Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Houli Zhao(Zhejiang University), Yongxian Hu(Zhejiang Lab), Jimin Shi(Zhejiang University), Mohamad Mohty(Inserm), Didier Blaise(Institut Paoli-Calmettes), Siguo Hao(Shanghai Jiao Tong University), Alex H. Chang, Mingfeng Zhao(Tianjin First Center Hospital), Elaine Tan Su Yin(Zhejiang University), Xianmin Song(Shanghai First People's Hospital), Yamin Tan(Zhejiang University), Yanmin Zhao(Zhejiang University), Arnon Nagler(Tel Aviv University), Jieping Wei(Zhejiang University), Jianmin Yang(Canadian Food Inspection Agency), Lei Xiao(Shanghai Cell Therapy Research Institute), Yi Luo(Hunan Cancer Hospital), Hongmei Jing(Peking University), Xin Li(Central South University), Jing Chen(Howard Hughes Medical Institute), Yuhua Li(Zhujiang Hospital), Ping Li(Tongji Hospital), Qing Zhang(Beijing Hospital of Traditional Chinese Medicine), Tao Wang(Second Military Medical University), He Huang(First Affiliated Hospital Zhejiang University), Wenjun Wu(Zhejiang University), Yunxiong Wei(Tianjin First Center Hospital), Jian Yu(Zhejiang University), Guoqing Wei(Zhejiang University), Qu Cui(Capital Medical University), Xiaoyu Lai(Zhejiang University), Aibin Liang(Tongji Hospital), Jing Huang(Peking University)
Cited by 82
Related Papers
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
|Nature Medicine|2023|534